Cardiometabolic comorbidities in autosomal dominant polycystic kidney disease: a 16-year retrospective cohort study
Abstract Background Autosomal-dominant polycystic kidney disease (ADPKD) is the most prevalent hereditary kidney disease and the fourth leading cause of end-stage renal disease (ESRD) requiring renal replacement therapy (RRT). Nevertheless, there is a paucity of epidemiological research examining th...
Main Authors: | Li-Chi Chen, Yi-Chi Chu, Tzongshi Lu, Hugo Y.-H. Lin, Ta-Chien Chan |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-11-01
|
Series: | BMC Nephrology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12882-023-03382-0 |
Similar Items
-
Kidney and cystic volume imaging for disease presentation and progression in the cat autosomal dominant polycystic kidney disease large animal model
by: Yoshihiko Yu, et al.
Published: (2019-07-01) -
Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
by: Raina R, et al.
Published: (2022-09-01) -
Autosomal dominant polycystic kidney disease: updated perspectives
by: Rastogi A, et al.
Published: (2019-08-01) -
Cyst Fraction as a Biomarker in Autosomal Dominant Polycystic Kidney Disease
by: Larina A. Karner, et al.
Published: (2022-12-01) -
Gallbladder cancer concomitant with autosomal dominant polycystic kidney disease: A case report
by: Hisashi Murakami, et al.
Published: (2022-12-01)